Navigation Links
Genomma Lab Internacional Revises 2009 Earnings Guidance
Date:9/8/2009

MEXICO CITY, Sept. 8 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), one of the fastest growing pharmaceutical and personal care products companies in Mexico with expansion into the international markets, announced today revisions to its earnings guidance for the full year of 2009. The Company expects net sales growth in the range of 35%-38% and an EBITDA margin of approximately 25%.

The revision of the Company's expected sales growth is mainly due to the higher sales anticipated from launches of the Company's recent acquisitions, namely Primer Nivel Por tu Salud(R), combined with a positive trend in demand for our base products in Mexico and in our existing international operations.

The Company is also slightly lowering its expected EBITDA margin due to the significant advertising investment required during the first months of a product launch. Once these launches stabilize, Genomma Lab expects their profitability margins to be in line with those of the rest of its portfolio.

It is important to highlight that this guidance revision is not contemplating sales from any geographic expansion of the Company's operations.

Genomma Lab will report third quarter results on October 26, 2009 and host a quarterly conference call the following business day.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico with an increasing presence in the international markets. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low- cost, highly flexible operating model.

Genomma's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:                          In New York:
    Oscar Villalobos-Torres           i-advize Corporate Communications, Inc.
    Tel: +52 55 5081-0000 Ext. 5106   Tel. (212) 406 3692
    e-mail: inversion@genommalab.co   e-mail: genommalab@i-advize.com

'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
2. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
3. Genomma Lab Internacional Acquires UNIGASTROZOL
4. Genomma Lab Announces 2009 Earnings Guidance
5. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
6. Genomma Lab Announces Initiation of Stock Repurchase Fund
7. Genomma Lab, New Participant in Market-Maker Program
8. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
9. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
10. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
11. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... , ... David J. Dykeman , Ginger Pigott , and ... at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg ... global Life Sciences & Medical Technology Group have been featured speakers at every DeviceTalks ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... 10.2 version gives development continuity to its innovative Unified Instance Manager architecture, ... capacity. In addition, this new version optimizes the unattended auto-dialing system without ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to ... convenient service for Texas, they are expanding their presence in Dallas. One of the ... that will bring new jobs to the Dallas and Forth Worth market. STAT takes ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... from offices headquartered in Hamilton County, is embarking on a charity drive with ... in finding new homes for orphaned or neglected senior dogs in the Cincinnati ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 Australia Glaucoma Surgery Devices ... new report, "Australia Glaucoma Surgery Devices Market Outlook ... Australia Glaucoma Surgery Devices market. The report provides ... units) and average prices (USD) within market segement ... provides company shares and distribution shares data for ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... to grow in 2017-2023. Various reasons for growth of ... population, higher incidences of chronic diseases, high recovery cost ... aid services. Medical lifting sling refers to an ... limited mobility. These slings connect to the lift and ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology: